Lund, Sweden—September 29, 2017—Dignitana (http://www.dignitana.se/eng/) AB,
a
world leader in medical scalp cooling technology and manufacturer of
the
DigniCap® Scalp Cooling System, today announces a decrease in 2017
sales
projections citing production delays.
The relocation of a major
manufacturer of the DigniCap® system resulted in a
production halt for two
months. This in turn has led to a reduction of product
availability, and thus,
Dignitana has not been able to deliver orders at a
planned amount. The move has
now been completed and production has returned to
normal capacity.
The
production halt will affect sales in Q3 and Q4 with approximately SEK
4
million. Dignitana will make efforts to deliver systems at a higher rate
during
Q4 and in Q1 of 2018, thus being able to recover parts of the
temporarily lost
sales.
Media Contacts:
Caren
Browning Semmy Rülf
King +
Company Chairman of the
board,
Dignitana AB
00 1 212 561-7464 +46
(0)709-312730
Caren.Browning@kingcompr.com
semmy.rulf@dignitana.se
About Dignitana AB (publ)
Dignitana is a Swedish
public company based in Lund and manufacturer of the
medical cooling device
DigniCap®. Dignitana AB is listed on Nasdaq First North
Stockholm and has
appointed Erik Penser Bank as Certified Adviser. Headquartered
in Dallas Texas,
Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For
more information
visit www.dignitana.se
About The DigniCap® Scalp Cooling System
DigniCap®
is a patented scalp cooling system that offers cancer patients the
ability to
keep their hair during chemotherapy. DigniCap® provides continuous
cooling with
high efficacy, safety and acceptable patient
comfort.
www.dignicap.com
###
This information is information that Dignitana
AB is obliged to make public
pursuant to the EU Market Abuse Regulation. The
information was submitted for
publication, by the above contact, for
publication at 14:30 (CET), 29
September 2017.
|